GlassScriptPhysician profile
Daljeet Bansal
NPI 1972691046
$483.23
in general payments reported to CMS, 2019-2025
12 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $157 · 2024: $87.81 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352 · Education: $23.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.62 |
| Education | $23.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $107.81 | 2022 | |
| Celgene Corporation | $78.52 | 2023-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $71.31 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $39.92 | 2023 | Fotivda |
| Abbvie INC. | $32.23 | 2024 | |
| Emd Serono, INC. | $30.97 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.28 | 2025 | |
| Karyopharm Therapeutics INC. | $23.80 | 2023 | Xpovio |
| Sobi, INC | $20.23 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.53 | 2025 | Danziten, Vivimusta |
| Mirati Therapeutics, INC. | $16.92 | 2023 | Krazati |
| Lilly USA, LLC | $16.71 | 2025 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljeet Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.